Cline Abigail, Berg Andrew, Bartos Gregory J, Strowd Lindsay C, Feldman Steven R
Drs. Cline, Berg, and Bartos are with the Center for Dermatology Research at the Wake Forest School of Medicine in Winston-Salem, North Carolina.
Dr. Strowd is with the Department of Social Sciences & Health Policy at the Wake Forest School of Medicine.
J Clin Aesthet Dermatol. 2020 Jun;13(6 Suppl):S33-S38. Epub 2020 Jun 1.
: Severe, recalcitrant cases of pediatric psoriasis or atopic dermatitis may necessitate treatment with biological agents; however, this may be difficult due to lack of treatment options and standardized treatment guidelines. This review evaluates the biological treatment options available, including off-label uses, and provides a basic therapeutic guideline for pediatric psoriasis and atopic dermatitis. : A PubMed review of biological treatments for pediatric psoriasis and atopic dermatitis with information regarding age, efficacy, dosing, contra-indications, adverse events, and off-label treatments. : Currently there are three European Medicines Agency (EMA)-approved biological treatment options for pediatric psoriasis: etanercept, ustekinumab, and adalimumab. While dupilumab was recently Food and Drug Administration (FDA)- and EMA-approved for adult atopic dermatitis, it is still not yet approved for pediatric atopic dermatitis. : Given the high morbidity associated with pediatric atopic dermatitis and psoriasis, there is a need for more treatment options. Further research and post-marketing registries are needed to extend the use of biologics into pediatric patients.
重度、难治性小儿银屑病或特应性皮炎病例可能需要使用生物制剂进行治疗；然而，由于缺乏治疗选择和标准化治疗指南，这可能会很困难。本综述评估了可用的生物治疗选择，包括超说明书用药，并为小儿银屑病和特应性皮炎提供了基本治疗指南。：对小儿银屑病和特应性皮炎的生物治疗进行PubMed综述，内容包括年龄、疗效、剂量、禁忌症、不良事件和超说明书治疗。：目前，欧洲药品管理局（EMA）批准了三种用于小儿银屑病的生物治疗选择：依那西普、乌司奴单抗和阿达木单抗。虽然度普利尤单抗最近获得了美国食品药品监督管理局（FDA）和EMA批准用于成人特应性皮炎，但尚未批准用于小儿特应性皮炎。：鉴于小儿特应性皮炎和银屑病的高发病率，需要更多的治疗选择。需要进一步的研究和上市后登记，以将生物制剂的使用扩展到小儿患者。
